Dual antiplatelet therapy following percutaneous coronary intervention: Clinical and economic impact of standard versus extended duration
Dual antiplatelet therapy (DAPT) -- the combination of a P2Y12 inhibitor (clopidogrel, prasugrel, or ticagrelor) together with ASA -- is routinely given following percutaneous coronary intervention (PCI) with stenting, with the aim of preventing stent thrombosis and other major adverse cardiac and c...
| Main Author: | |
|---|---|
| Corporate Author: | |
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
March 2019, 2019
|
| Series: | CADTH optimal use report, 1927-0127
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Table of Contents:
- Includes bibliographical references